Identifying medium-term future research priorities for seasonal malaria chemoprevention in Africa: An eDELPHI study

Authors: Kevin Baker, Ani Steele, Fangfang Lee, Susana Scott, Jean Louis Ndiaye, Sol Richardson

This study presents 10 medium-term SMC research priorities, which should guide new research and inform programme expansion and adaptation.

Seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine and amodiaquine (SPAQ) has been implemented in countries across the Sahel since 2014, reaching over 40 million children in 2022 alone. The scale-up of SMC has raised new research questions regarding its sustainability and whether it should be introduced in other geographical settings. Meanwhile, new World Health Organization recommendations have substantially increased implementers’ flexibility to tailor delivery models and eligibility criteria.

The SMC Alliance, established in 2013, brings together researchers and implementers focused on SMC delivery. The Alliance commissioned a consultation to identify SMC research priorities for the next 5–10 years.

This poster was presented at the Multilateral Initiative on Malaria (MIM) Society's 8th Pan-African Malaria Conference.